The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Official Title: A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors and Lymphomas
Study ID: NCT05279300
Brief Summary: This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 in patients with advanced hematological and solid tumors.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
North Shore Hematology Oncology Associates, East Setauket, New York, United States
Columbia U. - Herbert Irving Comprehensive Cancer Center, New York, New York, United States
BUMC - Mary Crowley Cancer Research Centers (MCCRC), Dallas, Texas, United States
Scientia Clinical Research Limited, Randwick, New South Wales, Australia
Ashford Cancer Centre Research, Adelaide, South Australia, Australia
Anhui Provincial Hospital,, Hefei, Anhui, China
Guangdong Province Hospital, Guangzhou, Guangdong, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Shandong Cancer Hospital, Jinan, Shandong, China
Shanghai East Hospital, Shanghai, Shanghai, China
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Beijing Cancer Hospital, Beijing, , China
Beijing Cancer Hospital, Beijing, , China
Fudan University Shanghai Cancer Hospital, Shanghai, , China